CSTL

Castle Biosciences Inc

Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 3,622 shares of the stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of...

Castle Biosciences to Present New Data Demonstrating DecisionDx-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS...

Shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten research firms that are presently covering the company, MarketBeat...

Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on...

Castle Biosciences (NASDAQ:CSTL) Trading Down 7% - What's Next...

Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year PR Newswire FRIENDSWOOD, Texas, April 10, 2026 FRIENDSWOOD, Texas, April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc...

Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 6,214 shares of the company's stock in a transaction dated Monday, April 6th. The stock was sold at an average...

Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at...

Castle Biosciences (NASDAQ:CSTL) executives and clinical collaborators used a DecisionDx-Melanoma webcast to review results from the multicenter DECIDE study, which the company said was recently published in Future Oncology. The discussion focused on how the company's 31-gene expression profile (31...